Prof. Dr. Alexander Schuhmacher

Forschung
- Pharma R&D models
- R&D efficiency
- Open innovation
- Artificial intelligence in pharma R&D
Vita
Akademische Ausbildung
- 2011-2012: Executive School of Management, Technology and Law, Universität St. Gallen (CH)
Executive MBA in General Management - 1999-2001: Universität Witten-Herdecke
Master of Science in Pharmaceutical Medicine - 1998-2001: Universität Konstanz
Kooperatives Doktorandenprogramm und Promotion zum Dr. rer. nat. - 1992-1997: Universität Konstanz
Studium der Biologie, Abschluss: Dipl. Biol.
Beruflicher Werdegang
- Seit 09/2021: Professor für Life Science Management
Technische Hochschule Ingolstadt - 2012 – 2021: Professor für Technologie- und Innovationsmanagement
Hochschule Reutlingen - 2011-2012: Geschäftsführer
Waldsee Golf Management GmbH - 2007 – 2010: Hauptabteilungsleiter, Strategic Planning & Business Support
Nycomed - 2004 – 2007: Abteilungsleiter, F&E Portfolio-Management
ALTANA Pharma AG - 2001 – 2004: Patentexperte
ALTANA Pharma AG - 1998 – 2000: Wissenschaftlicher Mitarbeiter/Doktorand, Abteilung Biochemie
Byk Gulden Lomberg
Veröffentlichungen
Eine Auswahl neuerer Publikationen (Fachartikel, peer-reviewed)
Schuhmacher A, Brieke C, Gassmann O, Hinder M, Hartl D. (2021) Systematic risk identification and assessment using a new risk map in pharmaceutical R&D. Drug Discov Today. 3: S1359-6446(21)00287-7. doi: 10.1016/j.drudis.2021.06.015.
Hartl D, de Luca V, Kostikova A, Laramie J, Kennedy S, Ferrero E, Siegel R, Fink M, Ahmed S, Millholland J, Schuhmacher A, Hinder M, Piali L, Roth A. (2021) Translational precision medicine: an industry perspective. J Transl Med. 19(1): 245. doi: 10.1186/s12967-021-02910-6.
Schuhmacher A, Gatto A, Kuss M, Gassmann O, Hinder M. Big Techs and startups in pharmaceutical R&D - A 2020 perspective on artificial intelligence (2021) Drug Discov Today 7: S1359-6446(21)00215-4. doi: 10.1016/j.drudis.2021.04.028.
Schuhmacher A, Wilisch L, Kuss M, Kandelbauer A, Hinder M, Gassmann O. (2021) R&D efficiency of leading pharmaceutical companies - A 20-year analysis. Drug Discov Today 26 (8):1784-1789. doi: 10.1016/j.drudis.2021.05.005.
Schuhmacher A, Gassmann O, Hinder M, Kuss M. (2021) The present and future of project management in pharmaceutical R&D. Drug Discov Today. 26(1): 1-4. doi: 10.1016/j.drudis.2020.07.020.
Schuhmacher A, Gatto A, Hinder M, Kuss M, Gassmann O. (2020) The upside of being a digital pharma player. Drug Discov Today. 25(9): 1569-1574. doi: 10.1016/j.drudis.2020.06.002.
Schuhmacher A, Kuss M. (2020) The impact of crowdsourcing in modern drug discovery. Expert Opin Drug Discov. 15(8): 865-867. doi: 10.1080/17460441.2020.1751116.
Schuhmacher, A., Gassmann, O., Kuss, M., Hinder, M. (2019) The Art of Virtualizing Pharma R&D. Drug Discovery Today 24: 2105-2107
Behbehani M., Glen A., Taylor C.S., Schuhmacher A., Claeyssens F., Haycock J.W. (2018) Pre-clinical evaluation of advanced nerve guide conduits using a novel 3D in vitro testing model. International Journal of Bioprinting 4: 123. http://dx.doi.org/10.18063/IJB.v4i1.123
Schuhmacher A., Gassmann O., McCracken N., Hinder M. (2018) Open innovation and external sources of innovation. An opportunity to fuel the R&D pipeline and enhance decision making? Journal of Translational Medicine. DOI: 10.1186/s12976-018-1499-2
Schuhmacher A, Gassmann O, Hinder M (2016) Changing R&D models in research‑based pharmaceutical companies. Journal of Translational Medicine, Vol. 14, pp. 105-115